EVD

External Ventricular Drain Market to Record a Growth of USD 2.28 billion between 2023 and 2028, North America to Occupy 35% Market Share - Technavio

Retrieved on: 
星期一, 一月 29, 2024
ROW, Geography, Sleep apnea, Subarachnoid hemorrhage, Gene, Stroke, PD, Birth, Epilepsy, USD, Brain, Chromosome, Traumatic brain injury, DSM-IV codes, EVD, Intracerebral hemorrhage, Ageing, Prevalence, Growth, Pharmaceutical industry

NEW YORK, Jan. 29, 2024 /PRNewswire/ -- The external ventricular drain market is estimated to grow by USD 2.28 billion from 2023 to 2028 at a CAGR of 6.07% according to Technavio.

Key Points: 
  • NEW YORK, Jan. 29, 2024 /PRNewswire/ -- The external ventricular drain market is estimated to grow by USD 2.28 billion from 2023 to 2028 at a CAGR of 6.07% according to Technavio.
  • North America accounts for 35% of the growth of the global market during the forecast period.
  • The external ventricular drain market in North America is poised for rapid expansion, propelled by the increasing prevalence of neurological disorders, the upsurge in the aging population, and advancements in technology.
  • Within this growth trajectory, ischemic strokes stand out as a significant driver of industry progression.

Maxwell Biosciences Announces Promising Activity of Claromer Compound Against Ebola Virus in a Research Study

Retrieved on: 
星期四, 十一月 2, 2023
Ebola, Virulence, Central Africa, Headache, Rocky Mountain Laboratories, Therapy, Vomiting, Diarrhea, Maxwell, Internal bleeding, Fever, Shock, Growth, Epidemic, Fatigue, RML, Biosafety level, Death, Peptide, BSL, EVD, Disease, Vaccine

The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.

Key Points: 
  • The data showed one of Maxwell's Claromer compounds is active against Ebola virus within the critical time frame required to address Ebola virus disease progression.
  • Once a human is infected, Ebola virus disease can be lethal within 4-5 days.
  • Maxwell is currently developing its Claromer drug platform, which has the potential to replace almost all antibiotics, antifungals and antivirals.
  • Since the first outbreak in Africa in 1976, several outbreaks and epidemics of Ebola virus have occurred in Western and Central Africa.

inTRAvent Medical Partners Names Dr. Kevin Foley Chief Innovation Officer

Retrieved on: 
星期二, 十月 17, 2023
Technology, Surgery, Medical Devices, Hospitals, Biotechnology, Health, Robotics, General Health, Artificial Intelligence, Remi, Knowledge, Barr v. American Assn. of Political Consultants, Inc., Neuro, Brain, Standard of care, MD, Caregiver, Safety, University, Hospice and palliative medicine, EVD, Congress of Neurological Surgeons, Anatomy, University of Tennessee Health Science Center, Patient, FDA, Artificial intelligence, 2D, CIO, ICU, Pathology, Biomedical engineering, Hematoma, Pharmaceutical industry, Nursing, Medical imaging, Management, Neurosurgery

inTRAvent Medical Partners LP , a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced the appointment of Kevin Foley, MD, in the newly created role of Chief Innovation Officer (CIO).

Key Points: 
  • inTRAvent Medical Partners LP , a medical device company dedicated to bringing intra-operative imaging and navigation to the bedside to improve neurosurgical procedures, today announced the appointment of Kevin Foley, MD, in the newly created role of Chief Innovation Officer (CIO).
  • Dr. Foley is a pioneer in neurosurgical navigation, with more than 175 U.S. patents to his name.
  • He serves on the boards of directors for several medical device and biologics companies, and is a recipient of the Cushing Award for Technical Excellence and Innovation in Neurosurgery from the American Assn.
  • We anticipate that his innovative spirit and visionary leadership will be pivotal to achieving our mission: enhancing the safety and precision of bedside neurosurgical procedures,” said inTRAvent co-founder and Chief Medical Officer Dr. Will Hazard.

Global Patient Temperature Monitoring Market Set for Remarkable Growth as Demand Surges for Advanced Monitoring Devices - ResearchAndMarkets.com

Retrieved on: 
星期一, 十月 9, 2023
Science, Other Science, Biotechnology, Medical Supplies, Health, Medical Devices, Hospitals, Health Technology, Select, Total, Stroke, Ebola, Incidence, Death, Fatality, Cardiovascular disease, EVD, Dietary supplement

No.

Key Points: 
  • No.
  • of Cases and Deaths Due to Ebola Virus Disease (EVD) Worldwide: 2014 to June 2017
    Global Population Statistics for the 65+ Age Group by Select Countries: 2019
    Total Preterm Births (in Percentage) in the US: 2010-2018E
    Fatalities by Heart Conditions - Estimated Percentage Breakdown for Cardiovascular Disease, Ischemic Heart Disease, Stroke, and Others
    Global Cancer Incidence: Number of New Cancer Cases in Million for the Years 2018, 2020, 2025, 2030, 2035 and 2040

European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older

Retrieved on: 
星期四, 九月 7, 2023
Biotechnology, General Health, Infectious Diseases, Health, Pharmaceutical, MSD, Vaccination, Chills, Public, Anaphylaxis, Arthralgia, Rash, Committee, Milk, Plasma, Risk, Committee for Medicinal Products for Human Use, European, EVD, NYSE, Saliva, Fatigue, Disease, Antigen, Pregnancy, Diarrhea, Urine, Somnolence, MRK, Appetite, UNICEF, Merck & Co., Myalgia, Vomiting, Child, Immunodeficiency, Headache, Ebola, Irritability, Mouth, Safety, Screaming, Fever, Civil service commission, Arthritis, History, Abdominal pain, Hyperhidrosis, IG, Allergy, Dizziness, Blood, European Medicines Agency, European Commission, Breast milk, CHMP, Infection, European Directive on Traditional Herbal Medicinal Products, RNA, Nausea, EC, Vaccine, Birth control, Merck, EU, Ebolavirus, Marburgvirus

The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.

Key Points: 
  • The vaccine was previously approved for use in the European Union (EU) for individuals 18 years of age or older.
  • “Ebola virus disease is severe and potentially life-threatening for both children and adults.
  • INDICATIONS AND USAGE IN THE U.S.
    ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

U.S. FDA Approves Merck’s ERVEBO® (Ebola Zaire Vaccine, Live) for Use in Children 12 Months of Age and Older

Retrieved on: 
星期四, 八月 3, 2023
Health, FDA, Infectious Diseases, Other Health, General Health, Pharmaceutical, Biotechnology, MSD, Vaccination, Marketing, Chills, Anaphylaxis, Arthralgia, Rash, Committee, Milk, Plasma, Risk, Committee for Medicinal Products for Human Use, European, EVD, NYSE, Saliva, Fatigue, Disease, Antigen, Pregnancy, Diarrhea, Urine, Somnolence, MRK, Appetite, UNICEF, Merck & Co., Myalgia, Vomiting, Child, Immunodeficiency, Headache, Irritability, Mouth, Safety, Screaming, Fever, Civil service commission, Arthritis, History, Abdominal pain, Hyperhidrosis, Ebola, IG, Allergy, Dizziness, Blood, European Medicines Agency, European Commission, Breast milk, CHMP, Infection, European Directive on Traditional Herbal Medicinal Products, RNA, Nausea, Regulation of tobacco by the U.S. Food and Drug Administration, Food, Pharmaceutical industry, Vaccine, Birth control, Merck, EU, Ebolavirus, Marburgvirus

The vaccine was previously approved for use in individuals 18 years of age and older.

Key Points: 
  • The vaccine was previously approved for use in individuals 18 years of age and older.
  • ERVEBO is currently authorized for use in the European Union (EU) for individuals 18 years of age and older.
  • ERVEBO® is indicated for the prevention of disease caused by Zaire ebolavirus in individuals 12 months of age and older.
  • Effectiveness of the vaccine when administered concurrently with antiviral medication, immune globulin (IG), and/or blood or plasma transfusions is unknown.

Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola

Retrieved on: 
星期一, 七月 31, 2023
ASPR, Emergent BioSolutions, Partnership, Biomedical Advanced Research and Development Authority, Office of Inspector General, U.S. Department of Health and Human Services, HHS, EBS, Ebola, Emergent, Global health, Government, Science, Administration, Development, Risk, Administration for Strategic Preparedness and Response, EVD, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, BARDA, NYSE, Food, Pharmaceutical industry

“For almost 25 years, Emergent has tackled the most serious diseases to assist governments in their preparedness and response strategies,” said Dr. Kelly Warfield, senior vice president, science and development at Emergent.

Key Points: 
  • “For almost 25 years, Emergent has tackled the most serious diseases to assist governments in their preparedness and response strategies,” said Dr. Kelly Warfield, senior vice president, science and development at Emergent.
  • “Ebola virus has the ability to emerge unexpectedly posing a risk to global health.
  • If all option periods are exercised, the total contract value will be valued at up to approximately $704 million.
  • This project has been funded in whole or in part with federal funds from HHS; ASPR; BARDA, under contract number 75A50123C00037.

EQS-News: Healthcare specialist SHS Capital sells Spiegelberg, a leading medtech expert for devices and consumables in the field of neurosurgery, to Luciole Medical

Retrieved on: 
星期二, 六月 27, 2023
Growth, SHS, EVD, Hospital, Acquisition, Neurosurgery, ICP, Brain, Catheter, Intracranial pressure, Jugular vein, Medical imaging, Management, Health care, Spiegelberg

Healthcare specialist SHS Capital sells Spiegelberg, a leading medtech expert for devices and consumables in the field of neurosurgery, to Luciole Medical

Key Points: 
  • Healthcare specialist SHS Capital sells Spiegelberg, a leading medtech expert for devices and consumables in the field of neurosurgery, to Luciole Medical
    The issuer is solely responsible for the content of this announcement.
  • Luciole Medical AG, which specialises in cerebral monitoring and measurement of oxygen saturation in the brain, is expanding its product range with the acquisition of Spiegelberg
    German healthcare specialist SHS Capital is selling its shares in Spiegelberg to Luciole Medical AG.
  • Spiegelberg, a medical technology company based in Hamburg, develops, produces and distributes highly specialised catheters and measuring probes for neurosurgical applications in the brain.
  • Founded in 1986, Spiegelberg has developed into a recognised provider in the field of intracranial pressure measurement.

AIM ImmunoTech Announces Late-Breaking Presentation at the International Conference on Antiviral Research Regarding Ampligen as a Potential Therapy Against Ebola Virus Disease

Retrieved on: 
星期四, 三月 16, 2023
Research, Conference, United States Army Medical Research Institute of Infectious Diseases, Mortality, Tropical disease, NYSE, RNA, Viral, Environmental science, Manuscript, University of Cagliari, International Conference on Emerging Infectious Diseases, ICAR, Ebola, Laboratory, AIM, Human, TLR3, PAMP, COVID-19, FDA, Disease, European Medicines Agency, Antiviral Research, EBOV, Doctor of Philosophy, Orphan drug, EVD, Investigational New Drug, Cancer, DSM-IV codes, Therapy, University, Vaccine, Pharmaceutical industry, Central Africa, Rintatolimod

Highlights of the recently published Ampligen data that was presented include:

Key Points: 
  • Highlights of the recently published Ampligen data that was presented include:
    As a TLR3 agonist, Ampligen induces and enhances innate immunological responses to EBOV infection.
  • AIM CEO Thomas K. Equels commented, “In vivo pre-clinical analysis shows that Ampligen has potential as both a prophylactic and an early-onset therapeutic in Ebola virus disease.
  • Animal studies with Ampligen at the United States Army Medical Research Institute of Infectious Diseases Biosafety Level 4 laboratories demonstrated 100% protective survival, as compared to 100% mortality in Ebola virus disease.
  • Ultimately, the Company's goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.

AIM ImmunoTech Announces Publication of New Analysis of the Mechanism of Action of Ampligen as a Potential Prophylactic Therapy Against Ebola Virus Disease

Retrieved on: 
星期三, 三月 8, 2023
AIM, EVD, Manuscript, TLR3, RNA, Mortality, Tropical disease, European Medicines Agency, PAMP, Physician, Cancer, NYSE, DSM-IV codes, Human, Orphan drug, Ebola, Research, EBOV, COVID-19, Disease, Antiviral Research, European, Investigational New Drug, Therapy, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Viral, MD, Food, Vaccine, Pharmaceutical industry, Rintatolimod, Central Africa

Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of Ebola virus disease (EVD) in Central Africa capable of reaching epidemic status.

Key Points: 
  • Ebola virus (EBOV) is a highly infectious and lethal pathogen responsible for sporadic, self-limiting clusters of Ebola virus disease (EVD) in Central Africa capable of reaching epidemic status.
  • Previously announced data found that Ampligen provided 100% protection against EVD in a mouse model.
  • The newly published analysis supports a dual mechanism of action when Ampligen is used as a prophylactic therapy against EVD.
  • Ultimately, the Company's goal is to seek a Tropical Disease Priority Review Voucher for new drug applications associated with these indications.